Found: 17
Select item for more details and to access through your institution.
Chemotherapy-induced gut toxicity: are alterations to intestinal tight junctions pivotal?
- Published in:
- Cancer Chemotherapy & Pharmacology, 2012, v. 70, n. 5, p. 627, doi. 10.1007/s00280-012-1989-5
- By:
- Publication type:
- Article
PPAR signaling pathway may be an important predictor of breast cancer response to neoadjuvant chemotherapy.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2012, v. 70, n. 5, p. 637, doi. 10.1007/s00280-012-1949-0
- By:
- Publication type:
- Article
Phase II study of irinotecan and cisplatin with concurrent split-course radiotherapy in limited-disease small cell lung cancer.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2012, v. 70, n. 5, p. 645, doi. 10.1007/s00280-012-1952-5
- By:
- Publication type:
- Article
Disposition and metabolism of (14)C-dovitinib (TKI258), an inhibitor of FGFR and VEGFR, after oral administration in patients with advanced solid tumors.
- Published in:
- 2012
- By:
- Publication type:
- Journal Article
Disposition and metabolism of C-dovitinib (TKI258), an inhibitor of FGFR and VEGFR, after oral administration in patients with advanced solid tumors.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2012, v. 70, n. 5, p. 653, doi. 10.1007/s00280-012-1947-2
- By:
- Publication type:
- Article
A phase II study of docetaxel and oxaliplatin combination in recurrent gastric cancer patients after fluoropyrimidine and/or cisplatin adjuvant treatment: a Korean Cancer Study Group Protocol ST06-02.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2012, v. 70, n. 5, p. 665, doi. 10.1007/s00280-012-1956-1
- By:
- Publication type:
- Article
A phase I and pharmacokinetic study of elisidepsin (PM02734) in patients with advanced solid tumors.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2012, v. 70, n. 5, p. 673, doi. 10.1007/s00280-012-1951-6
- By:
- Publication type:
- Article
A phase II study of concurrent chemoradiotherapy with weekly docetaxel and cisplatin in advanced oesophageal cancer.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2012, v. 70, n. 5, p. 683, doi. 10.1007/s00280-012-1962-3
- By:
- Publication type:
- Article
Phase I/II study of S-1 combined with biweekly irinotecan chemotherapy in previously treated advanced non-small cell lung cancer.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2012, v. 70, n. 5, p. 691, doi. 10.1007/s00280-012-1957-0
- By:
- Publication type:
- Article
Phase I and pharmacokinetic study of IHL-305 (PEGylated liposomal irinotecan) in patients with advanced solid tumors.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2012, v. 70, n. 5, p. 699, doi. 10.1007/s00280-012-1960-5
- By:
- Publication type:
- Article
Everolimus synergizes with gefitinib in non-small-cell lung cancer cell lines resistant to epidermal growth factor receptor tyrosine kinase inhibitors.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2012, v. 70, n. 5, p. 707, doi. 10.1007/s00280-012-1946-3
- By:
- Publication type:
- Article
Single-dose pharmacokinetics of lenalidomide in healthy volunteers: dose proportionality, food effect, and racial sensitivity.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2012, v. 70, n. 5, p. 717, doi. 10.1007/s00280-012-1966-z
- By:
- Publication type:
- Article
Population pharmacokinetics of farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2012, v. 70, n. 5, p. 727, doi. 10.1007/s00280-012-1959-y
- By:
- Publication type:
- Article
Phosphorylated AMP-activated protein kinase expression associated with prognosis for patients with gastric cancer treated with cisplatin-based adjuvant chemotherapy.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2012, v. 70, n. 5, p. 735, doi. 10.1007/s00280-012-1964-1
- By:
- Publication type:
- Article
A biomarker profile for predicting efficacy of cisplatin-vinorelbine therapy in malignant pleural mesothelioma.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2012, v. 70, n. 5, p. 743, doi. 10.1007/s00280-012-1965-0
- By:
- Publication type:
- Article
Phase I trial of pomalidomide given for patients with advanced solid tumors.
- Published in:
- 2012
- By:
- Publication type:
- Report
Erratum to: The 'survivin suppressants' NSC 80467 and YM155 induce a DNA damage response.
- Published in:
- 2012
- By:
- Publication type:
- Correction notice